Will2ride1 Posted - 04/30/24

$CANF ✅️

Danypoopoo Posted - 04/30/24

$CANF Decent volume

BigSqueezeComing Posted - 04/25/24

$CANF cancer news!!!

Stock_Titan Posted - 04/25/24

$CANF Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal https://www.stocktitan.net/news/CANF/long-term-complete-response-to-can-fite-s-namodenoson-in-patient-k6q53g2vxlrv.html

Pokemon69 Posted - 04/15/24

$CANF So, on the good news this scam goes down?

Pokemon69 Posted - 04/15/24

$CANF did you see? https://x.com/canfitepharma/status/1779830487571108054

DonCorleone77 Posted - 04/15/24

$CANF Can-Fite: Article by KOL presents Namodenoson to treat liver cancer, MASH Can-Fite BioPharma announced that Biomedicines published an article titled "Namodenoson at the Crossroad of Metabolic Dysfunction-Associated Steatohepatitis MASH and Hepatocellular Carcinoma, HCC...The article's first author, Dr. Ohad Etzion, is a renowned key opinion leader in the Hepatology field and is the engine for some of the novel drugs under development for the treatment of MASH and additional liver diseases. Dr. Etzion is the Head, Department of Gastroenterology and Liver Diseases, at Soroka University Medical Center, Beer Sheva, Israel. The Biomedicines article presents the pre-clinical and clinical activity of Namodenoson and the mechanism of action through which the drug induces the anti-cancer activity and at the same time the liver protective effects. This dual activity enables the drug to have positive effects in both liver cancer and MASH. Currently, Namodenoson is being evaluated in LiverationTM, a pivotal Phase III study for advanced liver cancer that has been approved by both the U.S. Food and Drug Administration FDA and the European Medicines Agency and also in a Phase IIb study in patients with MASH. "We are very much encouraged by the clinical data from the Phase II study in HCC and the Phase IIa study in MASH. The drug mechanism of action which is presented in the manuscript and entails inflammatory cytokine inhibition together with the stimulation of positive cytokines, position Namodenoson as a promising safe drug," stated Dr. Etzion.

Stock_Titan Posted - 04/15/24

$CANF Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH https://www.stocktitan.net/news/CANF/can-fite-scientific-article-published-by-kol-presents-namodenoson-as-nqfd5prj3eia.html

KingKhudayar Posted - 04/14/24

$CANF 30% drop on Monday

BioRich Posted - 04/09/24

$TRVI $CRMD $CANF were quiet for a bit but are starting to get attention. Buy and hold.

Erikg19 Posted - 04/05/24

$CANF

Erikg19 Posted - 04/05/24

$CANF Time for some volume. Let's see some activity next week and maybe something to push this higher. I added a little and ready to get more with an increase in volume.

BioRich Posted - 04/05/24

$AUPH let's finish the day green for once. Loading still happening on $VRNA and loving it. $CANF to finish green. Let's Gooooo!

Pokemon69 Posted - 04/04/24

$CANF whats going on? is it still alive?)

briefingcom Posted - 1 month ago

$CANF: Can-Fite BioPharma Submits FDA with an IND Application to conduct Phase IIb clinical trial of Namodenoson in MASH patients https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20240403071424CANF&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

DonCorleone77 Posted - 1 month ago

$CANF Can-Fite BioPharma submits IND to FDA for Phase IIb trial of namodenoson Can-Fite BioPharma announced submission of an investigational new drug, IND, application to the U.S. Food and Drug Administration, FDA, for the treatment of metabolic dysfunction-associated steatohepatitis, also known as non-alcoholic steatohepatitis, for the Company's ongoing Phase IIb clinical study. The Phase IIb trial is a multicenter, randomized, double-blind, placebo-controlled study in subjects with biopsy-confirmed MASH. "We are eager to look at the therapeutic effect of Namodenoson in patients with MASH," said Motti Farbstein, chief executive officer of Can-Fite. "Prior human data showed that treatment with Namodenoson leads to significant anti-MASH effects. Namodenoson's novel liver-protective mechanism of action provides a unique opportunity to potentially improve inflammation and reduce hepatic steatosis and fibrosis which may provide important therapeutic benefits for patients."

Stock_Titan Posted - 1 month ago

$CANF Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients https://www.stocktitan.net/news/CANF/can-fite-submits-fda-with-an-ind-application-to-conduct-phase-i-ib-j3z5in5hsjcf.html

BioRich Posted - 1 month ago

@Fendant $CANF is at least starting to show attention and price action. I see this as a very positive thing. $MRKR did that a couple weeks ago and had some nice movement. I think we go green 4 of 5 days this week.

TheWiredNomad Posted - 1 month ago

$CANF didn’t hold very well today

Erikg19 Posted - 1 month ago

$CANF spike w/ out volume can still be the indication of a move coming soon. With the conference coming up & the few drugs that could hit big I'll add today for the 1st time in a loooong time. It's still a very small position but I'm able to add multiple times as I see the interest grow here. GL #biotech

am2 Posted - 1 month ago

$CANF This is a tiny biotech with an impressive advanced pipeline. And, it is doing a presentation next week plus having "one on one meetings." I think this is exactly the kind of biotech that has the potential for a massive move within a short timeframe (e.g., day or two).

jhoffy Posted - 1 month ago

$CANF starting to get noticed. Still very early. But they have a conference next week and likely update on a few drugs which are very promising. Might be another $ALT going from 2's to over 10

BioRich Posted - 1 month ago

$OCGN so many haters. Long-term hold but short-term plays. A 12% dip on a huge sell is a great buy opportunity. Will be green for the week. Doing similar action that $CANF had. Knock it down to load the boat. Just how the game is played.

newsfile_corp Posted - 1 month ago

https://nfne.ws/203796 $CANF #InvitationalXIV #ldmicro #Publishing #Investing

Stock_Titan Posted - 1 month ago

$CANF Can-Fite BioPharma, Ltd. to Present at the LD Micro Invitational XIV https://www.stocktitan.net/news/CANF/can-fite-bio-pharma-ltd-to-present-at-the-ld-micro-invitational-zp6txp68bqbk.html

yoter Posted - 03/28/24

$CANF market cap of a measley ~ $9M, seems like a great bargain for a company with two phase3 potential blockbusters. By eoy 2024 if we get positive results, sp could skyrocket. Accumulate and hold strong.

epsguid Posted - 03/28/24

$CANF reported a loss of $0.31, consensus was ($0.27) via @eWhispers #epsmiss http://eps.sh/d/canf

Stock_Titan Posted - 03/28/24

$CANF Can-Fite Reports 2023 Financial Results and Clinical Update https://www.stocktitan.net/news/CANF/can-fite-reports-2023-financial-results-and-clinical-2nr5mfuw77z1.html

BioRich Posted - 03/28/24

$MRKR $JNCE and $CANF let's end the week strong

duder001 Posted - 03/27/24

$CANF WOW